Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 8:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 63 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cushing's Syndrome Clear all
Recruiting Not applicable Interventional

IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion

NCT07361874
View directory record Official record
Conditions
Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS), Subclinical Cushing's, Mild Autonomous Cortisol Excess
Interventions
Intervention 1: Adrenalectomy, Intervention 2: Semaglutide
Procedure · Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Jul 22, 2026, 8:14 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing's Syndrome.

NCT03277690
View directory record Official record
Conditions
Endogenous Cushing's Syndrome
Interventions
Levoketoconazole, Placebo
Drug
Lead sponsor
Cortendo AB
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
13
States / cities
Los Angeles, California • Fort Lauderdale, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Jul 22, 2026, 8:14 PM EDT
Completed Phase 2 Interventional Results available

New Imaging Techniques in the Evaluation of Patients With Ectopic Cushing Syndrome

NCT00001849
View directory record Official record
Conditions
Cushing Syndrome, Endocrine Disease
Interventions
Pentetreotide, 18F-DOPA, CT scan, MRI, 18-FDG
Drug · Device
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 90 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Jul 22, 2026, 8:14 PM EDT
Recruiting No phase listed Observational

Collecting Information About Treatment Results for Patients With Cushing's Syndrome

NCT03364803
View directory record Official record
Conditions
Cushing's Disease, Cushing Syndrome, Cushing Disease
Interventions
Cushing's QoL (Quality of Life Questionnaire), Nottingham Health Profile (NHP), Hospital Anxiety and Depression Scale (HADS), Perceived Stress Scale (PSS), Barratt's Impulsivity Scale (BIS), Beck Depression Inventory (BDI), State-Trait Anxiety Inventory (STAI), State Food Craving Questionnaire-State (FCQ-S), Trait Food Craving Questionnaire-Trait (FCQ-T), Visual Analogue Scale (VAS), Sensitivity to Reinforcement of Addictive and other Primary Rewards (STRAP-R) food variant
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
14 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Jul 22, 2026, 8:14 PM EDT
Recruiting Phase 2 Interventional

Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS)

NCT07104812
View directory record Official record
Conditions
Mild Autonomous Cortisol Secretion, Autonomous Cortisol Secretion (ACS)
Interventions
Osilodrostat 1 MG
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Jul 22, 2026, 8:14 PM EDT
Active, not recruiting Phase 2 Interventional

Metyrapone for Mild Autonomous Cortisol Secretion (MACS)

NCT06106295
View directory record Official record
Conditions
Autonomous Cortisol Secretion, Mild Autonomous Cortisol Secretion (MACS)
Interventions
Metyrapone
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Jul 22, 2026, 8:14 PM EDT
Terminated Phase 2 Interventional Results available

Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin

NCT00958841
View directory record Official record
Conditions
Pancreatic Neoplasm, Pituitary Neoplasm, Nelson Syndrome, Ectopic ACTH Syndrome
Interventions
pasireotide LAR
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
6
States / cities
Los Angeles, California • Stanford, California • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2016 · Synced Jul 22, 2026, 8:14 PM EDT
Completed Phase 2 Interventional

SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor

NCT05436639
View directory record Official record
Conditions
Autonomous Cortisol Secretion (ACS), ACTH-Independent Cushing Syndrome, ACTH-Independent Adrenal Cushing Syndrome, Somatic
Interventions
SPI-62 dose
Drug
Lead sponsor
Sparrow Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Rochester, Minnesota • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Jul 22, 2026, 8:14 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Study of Hypercortisolism in Cushing's Syndrome and Stress-Induced Pseudo-Cushing's Syndrome

NCT00004343
View directory record Official record
Conditions
Cushing's Syndrome
Interventions
Not listed
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
0 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1999
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 22, 2026, 8:14 PM EDT
Active, not recruiting Phase 2 Interventional

Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome

NCT03604198
View directory record Official record
Conditions
Cushing Syndrome
Interventions
relacorilant
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
Not listed
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
25
States / cities
Phoenix, Arizona • Stanford, California • Torrance, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Jul 22, 2026, 8:14 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Desmopressin Stimulation Test Performance in ACTH-Dependent Cushing Syndrome

NCT06635629
View directory record Official record
Conditions
Cushing Syndrome
Interventions
Desmopressin, Dexamethasone
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 70 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 22, 2026, 8:14 PM EDT
Completed No phase listed Observational

Study of the Prevalence of Endogenous Hypercortisolism in Patients With Resistant Hypertension (MOMENTUM)

NCT06829537
View directory record Official record
Conditions
Resistant Hypertension, Hypercortisolism
Interventions
Not listed
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
1,143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
50
States / cities
Huntington Park, California • La Jolla, California • Los Angeles, California + 42 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Jul 22, 2026, 8:14 PM EDT
Recruiting Phase 4 Interventional

Isturisa Treatment in Mild Autonomous Cortisol Secretion( MACS)

NCT07247058
View directory record Official record
Conditions
Mild Autonomous Cortisol Secretion (MACS)
Interventions
Osilodrostat (Isturisa)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Jul 22, 2026, 8:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants

NCT05347979
View directory record Official record
Conditions
Cushing Syndrome, Neoplasms
Interventions
Dabigatran Etexilate, Relacorilant
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Jul 22, 2026, 8:14 PM EDT
Completed No phase listed Observational

Jugular Vein Sampling for Hormone Levels for the Diagnosis of Cushing Syndrome

NCT00001453
View directory record Official record
Conditions
Cushing's Syndrome
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 75 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Jul 22, 2026, 8:14 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Dynamics of Leptin and Endocrine Function

NCT00001543
View directory record Official record
Conditions
Healthy, Involutional Depression
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1996 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 22, 2026, 8:14 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Evaluation of Adults With Endocrine and Metabolic-Related Conditions

NCT02830308
View directory record Official record
Conditions
Endocrine Diseases
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 100 Years
Enrollment
1,250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Jul 22, 2026, 8:14 PM EDT
Recruiting Phase 2 Interventional

Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome

NCT03708900
View directory record Official record
Conditions
Cushing Syndrome
Interventions
LCI699
Drug
Lead sponsor
RECORDATI GROUP
Industry
Eligibility
2 Years to 17 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
5
States / cities
San Francisco, California • Cape Coral, Florida • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Jul 22, 2026, 8:14 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas

NCT04308590
View directory record Official record
Conditions
Hypercortisolism
Interventions
Relacorilant, Placebo
Drug · Other
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
22
States / cities
Birmingham, Alabama • Stanford, California • Torrance, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Jul 22, 2026, 8:14 PM EDT
Withdrawn Phase 3 Interventional

Mifepristone in Children With Refractory Cushing's Disease

NCT01925092
View directory record Official record
Conditions
Cushing's Disease
Interventions
mifepristone
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
6 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 3, 2014 · Synced Jul 22, 2026, 8:14 PM EDT
Completed No phase listed Observational

Hippocampal Complex Volume and Memory Dysfunction in Cushing's Syndrome

NCT00004326
View directory record Official record
Conditions
Cushing's Syndrome
Interventions
Not listed
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
15 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1994
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 22, 2026, 8:14 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cognition, Steroids, and Imaging in Cushings Disease

NCT00081341
View directory record Official record
Conditions
Cushing Syndrome
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
9 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2002
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 14, 2010 · Synced Jul 22, 2026, 8:14 PM EDT
Withdrawn Phase 2 Interventional

SOM230 Ectopic ACTH-producing Tumors

NCT02780882
View directory record Official record
Conditions
Ectopic ACTH Syndrome
Interventions
Pasireotide
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2018 · Synced Jul 22, 2026, 8:14 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Mifepristone Effects on Glucose Intolerance in Obese/Overweight Adults

NCT01419535
View directory record Official record
Conditions
Endocrine Disease, Diabetes
Interventions
Mifepristone, Placebo
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
35 Years to 70 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Jul 22, 2026, 8:14 PM EDT